EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B‐Cell Population

Geir Erland Tjønnfjord iD, Liv Toril N Osnes, Signe Spetalen, Ulla Haave iD, Trine H Popperud, Angelina H Maniaol, Ingunn Østlie, Livia Bajelan, Lars Henrik D Hamnvik, Kristo Marvyin, Dragana Miskovic, Eirik B Tjønnfjord und 5 weitere

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/1959235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 03.07.2026. Verfasst von Geir Erland Tjønnfjord und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no. Hauptthemen laut MEDLINE: Myelin-Associated Glycoprotein, Polyneuropathies, B-Lymphocytes, Paraproteinemias. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polyneuropathy due to antibodies to myelin‐associated glycoprotein (MAG) is a rare disease with an estimated prevalence of 1 per 100,000. Symptoms start in the sixth or seventh decade of life, presenting sensory polyneuropathy with sensory ataxia, paresthesia, mild motor deficit, and tremor of upper extremities. The neurophysiological features are compatible with length‐dependent demyelination. It is caused by monoclonal gammopathy of the IgM type produced by clonal B cells. In recent years the monoclonal anti‐CD20 antibody has become the preferred first‐line treatment, but with limited efficacy. We identified a cohort of 42 patients diagnosed with anti‐MAG polyneuropathy. Clinical data were collected retrospectively, and flow cytometry files and immune histochemistry slides were reassessed. We report that in most cases of anti‐MAG polyneuropathy, the monoclonal IgM is kappa‐restricted, the B‐cell population shows lymphoplasmacytic differentiation, MYD88 L265P mutation is a frequent finding, and the clonal B‐cell population includes plasma cells. These findings most likely explain the low efficacy of rituximab monotherapy. We found the burden of symptoms to be high among patients with anti‐MAG polyneuropathy as most of our patients had received intravenous immunoglobulin infusions and/or B‐cell‐directed treatment. We suggest that future treatment protocols for anti‐MAG polyneuropathy should incorporate plasma cell‐directed drugs. Furthermore, we found complement receptor 1 (CD35) to be down regulated on clonal B lymphocytes but not on normal B lymphocytes in these patients. We suggest that this may be a common feature of clonal B lymphocytes in chronic lymphoproliferative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin-Associated GlycoproteinPolyneuropathiesB-LymphocytesParaproteinemiasHumansFemaleMaleMiddle AgedAutoantibodiesAgedImmunoglobulin MRetrospective StudiesAged, 80 and overRituximabPlasma CellsAdult

Substanzen

Myelin-Associated GlycoproteinAutoantibodiesImmunoglobulin MRituximab

Autor:innen und Institutionen

  • Department of Haematology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway, uio.no.
  • Department of Immunology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
  • Department of Pathology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.
  • Department of Pathology, Akershus University Hospital, Lørenskog, Norway, ahus.no.
  • Department of Neurology, Oslo University Hospital, Oslo, Norway, oslo-universitetssykehus.no.

ORCID-Profile: Geir Erland Tjønnfjord, Ulla Haave, Agnieszka Malecka

Zitieren

APA

Tjønnfjord, G. E., Osnes, L. T. N., Spetalen, S., Haave, U., Popperud, T. H., Maniaol, A. H., Østlie, I., Bajelan, L., Hamnvik, L. H. D., Marvyin, K., Miskovic, D., Tjønnfjord, E. B., Winje, K., Moksnes, M., Tvedt, T. H. A., Kvam, A. K., & Malecka, A. (2026). Anti‐MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B‐Cell Population. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/1959235

Vancouver

Tjønnfjord GE, Osnes LTN, Spetalen S, Haave U, Popperud TH, Maniaol AH, et al. Anti‐MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B‐Cell Population. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/1959235

BibTeX
@article{Tjnnfjord2026,
  author = {Tjønnfjord, Geir Erland and Osnes, Liv Toril N and Spetalen, Signe and Haave, Ulla and Popperud, Trine H and Maniaol, Angelina H and Østlie, Ingunn and Bajelan, Livia and Hamnvik, Lars Henrik D and Marvyin, Kristo and Miskovic, Dragana and Tjønnfjord, Eirik B and Winje, Kristoffer and Moksnes, Magnus and Tvedt, Tor Henrik A and Kvam, Ann Kristin and Malecka, Agnieszka},
  title = {Anti‐MAG Polyneuropathy: Characterization of the Monoclonal Gammopathy and Clonal B‐Cell Population},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/1959235}
}
Kostenlos starten →